HHS ends COVID EUA declarations for drugs and devices
United States Public Health Safety and Legal Rules – HHS is ending COVID emergency-use declarations for drugs, biologics and devices, but the phaseout is staggered.
HHS has formally ended the COVID-19 emergency-use authorization declarations for drugs and biological products, as well as for medical devices. The change is not immediate: the drug and biologic declaration will terminate 12 months after the secretary’s determination, while the device declarations will end after 180 days.
That matters because emergency-use authorizations are the legal tool FDA uses to allow unapproved products, or unapproved uses of approved products, during an emergency when there are no adequate approved and available alternatives. HHS said the public-health conditions that justified those COVID-era declarations no longer exist.
An orderly unwind, not a sudden stop
HHS said the notice periods are meant to give manufacturers, health systems, distributors, providers and patients time to move away from products authorized only under the COVID EUA declarations. In practical terms, that can affect purchasing, inventory planning, labeling and documentation, especially for facilities that still have emergency-authorized products in stock or in procurement pipelines.
The department also said HHS and FDA will keep working with manufacturers on the normal pathways for products that seek traditional approval, clearance or licensure. Ending the declarations is not the same as an immediate ban on every COVID-era product, and it is not a blanket safety finding. Some products may continue under ordinary FDA pathways if they qualify.
What to watch next
The next question is product-specific: which drugs, biologics, tests and devices move into standard review, and which ones fall off the emergency-only track as the notice periods run out? HHS said it will publish the terminations in the Federal Register and send the required congressional notices.
For patients, the likely result is a gradual transition rather than a sudden disruption. For providers and distributors, the key task is to identify which items are still covered only by emergency authority and plan replacements before the deadlines arrive.
Sources
- HHS press release: HHS ends COVID-19 emergency-use authorizations
- Health.gov mirror: HHS Secretary Kennedy signs COVID-19 EUA declaration terminations
- FDA background: Emergency Use Authorization framework
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.
